JB Pharma Q2 Results: Net profit jumps 35% YoY to Rs 151 crore

JB Pharma on Tuesday reported a 35% year-on-year (YoY) jump in net profit Rs 151 crore for the July-September quarter of FY24. The drug maker had reported a net profit of Rs 111 crore in the year-ago period.

Revenue for the quarter rose 9% YoY to Rs 882 crore. The Mumbai-based company reported operating earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 251 crore, up from Rs 202 crore in the year-ago period.

The operating EBITDA margin improve 350 basis points YoY to 28.5%. Domestic formulations business reported 11% YoY growth to Rs 481 crore in Q2 FY24.


International business registered 7% YoY growth to Rs 401 crore. CDMO business recorded revenue of Rs 115 crores registering YoY revenue growth of 5%.

“During Q2, the business delivered a healthy blend of domestic and international business growth, with expansion in domestic business led by our chronic segment and acquired portfolio," said CEO Nikhil Chopra in a press statement.

"Our transformed go-to-market framework is driving gains in market share and improvement in our rankings in IPM. Our acquired portfolio has not only helped us increase our chronic segment presence and market rankings, but it is also beginning to positively impact our operating margins,” Chopra added.